Physician profile
Joann H Eriksson
NPI 1588018311
$8,327.43
in general payments reported to CMS, 2019-2025
23 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what 96% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,972 · 2023: $2,720 · 2024: $1,450 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,793 · Education: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,793.43 |
| Education | $561.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,509.78 | 2022-2025 | Enhertu, Lynparza, Tagrisso |
| Janssen Biotech, INC. | $1,019.31 | 2022-2025 | Rybrevant, Carvykti, Imbruvica |
| Regeneron Healthcare Solutions, INC. | $619.58 | 2022-2025 | Libtayo |
| Incyte Corporation | $502.54 | 2022-2025 | Monjuvi, Jakafi |
| Sobi, INC | $501.23 | 2023-2025 | |
| Gilead Sciences, INC. | $493.84 | 2022-2024 | Trodelvy |
| Jazz Pharmaceuticals INC. | $386.36 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $358.58 | 2022-2025 | Opdivo |
| Abbvie INC. | $349.78 | 2022-2025 | |
| Seagen INC. | $333.07 | 2022-2023 | Tukysa |
| Alexion Pharmaceuticals, INC. | $310.93 | 2022-2023 | Ultomiris |
| Genzyme Corporation | $306.10 | 2022-2023 | |
| Emd Serono, INC. | $253.15 | 2023-2024 | Tepmetko |
| Amgen INC. | $244.14 | 2023-2024 | Nplate |
| Daiichi Sankyo INC. | $205.77 | 2023-2025 | Enhertu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $150.00 | 2022 | |
| Beigene USA, INC. | $133.51 | 2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $127.46 | 2023 | |
| G1 Therapeutics, INC. | $122.54 | 2023 | Cosela |
| Merck Sharp & Dohme LLC | $108.75 | 2024-2025 | Keytruda |
| Kite Pharma, INC. | $104.17 | 2023 | |
| Puma Biotechnology, INC. | $99.84 | 2022 | |
| Exelixis INC. | $87.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Eriksson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.